Advisor Group Inc. Sells 2,027 Shares of Hologic, Inc. (HOLX)
Advisor Group Inc. lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 24.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,330 shares of the medical equipment provider’s stock after selling 2,027 shares during the quarter. Advisor Group Inc.’s holdings in Hologic were worth $232,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in HOLX. Parnassus Investments CA acquired a new stake in shares of Hologic during the 3rd quarter worth approximately $277,062,000. Capital World Investors bought a new position in shares of Hologic during the 2nd quarter worth approximately $312,441,000. HealthCor Management L.P. bought a new position in shares of Hologic during the 2nd quarter worth approximately $76,604,000. Columbus Circle Investors bought a new position in shares of Hologic during the 2nd quarter worth approximately $54,511,000. Finally, Vanguard Group Inc. lifted its position in shares of Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after buying an additional 1,200,825 shares during the period. 93.80% of the stock is currently owned by institutional investors.
Several equities analysts recently commented on HOLX shares. BidaskClub downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Royal Bank Of Canada cut their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Thursday, August 3rd. Goldman Sachs Group downgraded Hologic from a “conviction-buy” rating to a “buy” rating and cut their target price for the stock from $48.00 to $47.00 in a research report on Thursday, August 3rd. Deutsche Bank cut their target price on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Finally, Barclays cut their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $47.54.
In other Hologic news, Director Lawrence M. Levy sold 7,138 shares of Hologic stock in a transaction on Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,972 shares of company stock valued at $1,385,977. Corporate insiders own 0.79% of the company’s stock.
Hologic, Inc. (NASDAQ HOLX) opened at $42.27 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80. The stock has a market capitalization of $11,151.40, a price-to-earnings ratio of 20.02, a price-to-earnings-growth ratio of 1.96 and a beta of 0.93.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same quarter in the previous year, the company posted $0.52 EPS. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. equities research analysts expect that Hologic, Inc. will post 2.12 earnings per share for the current year.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.